ReviewThorax2007
Pathological networking: a new approach to understanding COPD.
Review in Thorax, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Scale-free networks in metabolomics.Bioinformation · 2018Article
- Article
- Tracing personalized health curves during infections.PLoS biology · 2011Article
- Role of interleukin-1 and MyD88-dependent signaling in rhinovirus infection.Journal of virology · 2011Article
- Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.Journal of the National Cancer Institute · 2009Article
- Targeted treatment in COPD: a multi-system approach for a multi-system disease.International journal of chronic obstructive pulmonary disease · 2009Review
- A phosphatidylserine species inhibits a range of TLR- but not IL-1beta-induced inflammatory responses by disruption of membrane microdomains.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
Corrections and comments
- Reprinted as
Authors and funding
5 authors.
Funding
Abstract
Developing new treatments for chronic obstructive pulmonary disease (COPD) is extremely challenging. This disease, chronic by definition, becomes apparent only after substantial-and probably irreversible-tissue damage has occurred. The observable phenotype is of a stable disease state whose progression is hard to influence and reversal of which appears almost impossible. Identifying key components of the pathological process, targeting of which will result in substantial clinical benefit, is a significant challenge. In this review the nature of the disease is examined and conceptual information and simple tissue models of inflammation are used to explore the pathological network that is COPD. From the concept of COPD as a disease network displaying the features of contiguous immunity (in which many processes of innate and adaptive immunity are in continual dialogue and evolution), refinements are suggested to the strategies aimed at developing effective new treatments for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.